Compare Southwest Airlines Co (LUV) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Summit Therapeutics Inc — how do they compare? Southwest Airlines Co trades at $45.05 (market cap $22.27B), while Summit Therapeutics Inc trades at $15.19 (market cap $12.06B). The key difference: Southwest Airlines Co is the larger of the two by market cap, and Southwest Airlines Co pays a 1.58% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LUV | SMMT | |
|---|---|---|
Market Cap | $22.27B | $12.06B |
Sector | Industrials | Health |
52-Week High | $54.80 | $26.98 |
52-Week Low | $29.67 | $12.55 |
Enterprise Value | $25.37B | $11.39B |
Dividend Yield | 1.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $44.91, showing minimal daily movement. The stock exhibits a bearish technical trend, with key support at $45 and resistance at $46. Fundamentally, revenue grew to $28.06B in 2025, though net income margin compressed to 1.57%. Recent Q2 2026 earnings beat expectations with EPS of $0.94 versus $0.51 expected, while Q1 2026 missed. The company maintains a dividend of $0.18 per share and is focusing on business travel expansion.
LUV presents a mixed outlook. Analyst consensus is a Buy with a $53.86 price target, implying ~20% upside, supported by earnings rebound and strategic initiatives. However, risks include fuel cost volatility, competitive pressures, and bearish technical indicators. Investors should weigh solid liquidity and growth initiatives against margin pressures and macroeconomic sensitivities.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
